CLINICAL TRIALS PROFILE FOR SELENIOUS ACID

All Clinical Trials for SELENIOUS ACID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05136378 ↗	Selenious Yeast in CLL Patients w/o Indication of Chemotherapy	Recruiting	Shanghai Changzheng Hospital	N/A	2021-11-01	The purpose of this study is to evaluate the safety and effectiveness of Selenious Yeast Tablets in Chronic Lymphocytic Leukemia Patients without Indication of Chemotherapy
NCT05136378 ↗	Selenious Yeast in CLL Patients w/o Indication of Chemotherapy	Recruiting	Shanghai Zhongshan Hospital	N/A	2021-11-01	The purpose of this study is to evaluate the safety and effectiveness of Selenious Yeast Tablets in Chronic Lymphocytic Leukemia Patients without Indication of Chemotherapy
NCT05661682 ↗	Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Product Safety in Adult Patients Requiring Long-term Parenteral Nutrition	Not yet recruiting	American Regent, Inc.	Phase 4	2022-12-31	Tralement versus a fixed-dose trace element combination product of zinc, copper, and selenious acid to evaluate product safety in adult patients requiring long-term parenteral nutrition.
NCT05677126 ↗	Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Product Safety in Pediatric Patients >3 to 17 Years of Age Requiring Long-term Parenteral Nutrition	Not yet recruiting	American Regent, Inc.	Phase 4	2022-12-31	Tralement versus a fixed-dose trace element combination product of zinc, copper, and selenious acid to evaluate product safety in pediatric patients >3 to 17 years of age requiring long-term parenteral nutrition.

Clinical Trial Conditions for SELENIOUS ACID

Condition Name

Condition Name for SELENIOUS ACID
Intervention	Trials
Chronic Lymphocytic Leukaemia Stage B(I)	1
Chronic Lymphocytic Leukemia Stage A(0)	1
Chronic Lymphocytic Leukemia Stage A(I)	1
Chronic Lymphocytic Leukemia Stage A(II)	1

Condition MeSH

Condition MeSH for SELENIOUS ACID
Intervention	Trials
Leukemia, Lymphocytic, Chronic, B-Cell	1
Leukemia	1
Leukemia, Lymphoid	1

Clinical Trial Locations for SELENIOUS ACID

Trials by Country

Trials by Country for SELENIOUS ACID
Location	Trials
China	1

Clinical Trial Progress for SELENIOUS ACID

Clinical Trial Phase

Clinical Trial Phase for SELENIOUS ACID
Clinical Trial Phase	Trials
Phase 4	2
N/A	1

Clinical Trial Status

Clinical Trial Status for SELENIOUS ACID
Clinical Trial Phase	Trials
Not yet recruiting	2
Recruiting	1

Clinical Trial Sponsors for SELENIOUS ACID

Sponsor Name

Sponsor Name for SELENIOUS ACID
Sponsor	Trials
American Regent, Inc.	2
Shanghai Changzheng Hospital	1
Shanghai Zhongshan Hospital	1

Sponsor Type

Sponsor Type for SELENIOUS ACID
Sponsor	Trials
Other	2
Industry	2

Last updated: July 24, 2026

Selenious Acid Clinical Trials Update, Market Analysis, and Market Projections (2026)

No market and clinical-trial update can be produced for “selenious acid” from the information provided.

What clinical trials exist for selenious acid, and which indications are in scope?

No complete, source-backed clinical trial inventory can be generated.

Which trial phases and endpoints are reported

No phase, endpoint, or enrollment data can be generated.

Who sponsors and operates the studies

No sponsor or CRO/operator details can be generated.

Where trials are registered

No registry coverage (e.g., ClinicalTrials.gov, EU CTR, ISRCTN) can be generated.

What is the Orange Book status of selenious acid in the US?

No source-backed Orange Book status can be generated.

Is selenious acid listed as an active ingredient

No listing or reference-product mapping can be generated.

Are there approved generic equivalents or branded products

No FDA approval or equivalence status can be generated.

Which patents protect selenious acid, and how many are active?

No patent estate can be produced.

Composition-of-matter and formulation patents

No composition-of-matter, salt, hydrate, or formulation patent coverage can be generated.

Method-of-use and dosing patents

No method-of-use coverage can be generated.

Manufacturing and impurity-control IP

No manufacturing-process or impurity-specification IP can be generated.

When does selenious acid lose exclusivity, and what generic entry risks exist?

No exclusivity timeline can be generated.

Hatch-Waxman exclusivity types potentially relevant

No 180-day, 3-year, 5-year, or pediatric exclusivity mapping can be generated.

Paragraph IV challenge likelihood

No Paragraph IV filing or risk assessment can be generated.

How strong is the patent estate for selenious acid by jurisdiction?

No strength assessment can be generated.

US vs. EP vs. JP coverage

No jurisdictional breakdown can be generated.

Litigation history and PTAB outcomes

No litigation record can be generated.

Is there a biosimilar or biobetter pathway for selenious acid?

No biosimilar pathway can be generated for this product term.

What drug product forms are marketed for selenious acid, and what formulations are protected?

No marketed dosage forms, label claims, or protected formulations can be generated.

Oral, parenteral, and topical availability

No route-of-administration availability can be generated.

Salt forms, hydrates, and controlled-release versions

No specific chemical forms or controlled-release versions can be generated.

Which companies are developing or commercializing selenious acid, and how do their pipelines compare?

No company- and pipeline-level comparison can be generated.

What does the FDA regulatory pathway look like for selenious acid (NDA, ANDA, 505(b)(2))?

No FDA pathway mapping can be generated.

Key milestones and submission history

No IND/NDA/ANDA/505(b)(2) milestones can be generated.

Orphan or fast-track designations

No designation data can be generated.

How much revenue exposure exists for selenious acid by region and indication?

No revenue model can be generated.

Market size projections for selenious acid: base, bull, and bear scenarios

No forecast can be generated.

Key Takeaways

• No source-backed clinical trial update or market projection can be produced for “selenious acid” based on the information provided.

FAQs

1. Is selenious acid approved by the FDA for any indication?
2. Are there any active ClinicalTrials.gov studies for selenious acid?
3. What patents cover selenious acid formulations or dosing?
4. Could generic or 505(b)(2) products enter the market for selenious acid soon?
5. Which manufacturers sell selenious acid drug products or dietary/medical products?

References

1. (No cited sources available.)